Why I think these 3 blue-chip shares are great buys now

Credit: U.S. Army RDECOM

In the coming years, Australia’s economy will continue to transition away from the mining and resources sectors towards those industries with more sustainable growth trajectories.

While the success of a ‘top-down’ stock-picking strategy (i.e picking stocks based on industry tailwinds) is questionable, investing in companies with good economics and natural tailwinds can produce exceptional returns over time.

Technology companies provide a way forward, so too does tourism and, to a lesser extent, agriculture. Another two sectors of our economy that I believe could be set for long-term growth are healthcare and biotechnology. Australia has a robust healthcare system, which is aided by a strong regulatory environment and a robust educational system.

Further, innovative biotechnology companies are usually rewarded for their time and capital with patents and have proven their ability to transverse international borders.

The next three blue chip shares provide a viable avenue for savvy long-term investors to exploit the healthcare and biotechnology tailwinds. Indeed, even at today’s prices, I urge you to consider adding them to your watchlist — at the very least.

  1. The CSL Limited (ASX: CSL) share price recently popped back above $100. CSL is a world-leader in the research, development and marketing for blood plasma products. Its products are used to prevent and treat complex disorders affecting many people throughout the world.
  2. ResMed Inc. (CHESS) (ASX: RMD) is also a leader in its industry. It produces devices for the treatment of sleep apnoea and related respiratory disorders. Its continuous positive airway pressure (CPAP) and automatic positive airway pressure (APAP) machines aren’t cheap, but have proven to be among the most effective in the industry.
  3. Like ResMed and CSL, Cochlear Limited (ASX: COH) is a name familiar to many Australians. The Cochlear range of hearing devices are also very popular throughout the world, and the company operates in more than 20 countries. Despite a recent rebound in share price, however, Cochlear appears a worthwhile investment over the long term.

Buy, Hold or Sell?

I think CSL, ResMed and Cochlear are among the ASX’s best blue chip stocks, and their performance over the next 10 years will speak for itself. While they may appear expensive using conventional valuation metrics like a price-earnings ratio (P/E), I’m willing to pay up for the right to hold quality businesses like these for the long term.

Our BEST dividend stock idea

I think CSL, ResMed and Cochlear are good buys right now, but - I'll admit - they don't have BIG dividends like some other ASX companies. Fortunately, The Motley Fool has just issued a brand-new report, complete with all the details on our expert analysts' #1 dividend stock for 2016. Simply, click here now for your FREE copy, including the name and code! No credit card details or payment required. 

Motley Fool writer/analyst Owen Raszkiewicz owns shares of CSL, ResMed and Cochlear. 

Owen welcomes your feedback on Google plus (see below), LinkedIn or you can follow him on Twitter @ASXinvest.

Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.